NYSE American - Delayed Quote USD

NeurAxis, Inc. (NRXS)

2.2660
-0.0340
(-1.48%)
At close: May 14 at 3:59:53 PM EDT
Loading Chart for NRXS
  • Previous Close 2.3000
  • Open 2.3000
  • Bid 2.0000 x 3100
  • Ask 2.2700 x 1300
  • Day's Range 2.2100 - 2.3700
  • 52 Week Range 1.3300 - 3.7800
  • Volume 10,667
  • Avg. Volume 28,475
  • Market Cap (intraday) 16.351M
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -1.2200
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 4.75

NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. The company offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8-21 years of age with functional abdominal pain associated with irritable bowel syndrome. It sells its products to healthcare companies, such as hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. NeurAxis, Inc. was founded in 2011 and is headquartered in Carmel, Indiana.

neuraxis.com

21

Full Time Employees

December 31

Fiscal Year Ends

Recent News: NRXS

View More

Performance Overview: NRXS

Trailing total returns as of 5/14/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

NRXS
3.57%
S&P 500 (^GSPC)
0.19%

1-Year Return

NRXS
19.65%
S&P 500 (^GSPC)
12.31%

3-Year Return

NRXS
64.03%
S&P 500 (^GSPC)
46.44%

5-Year Return

NRXS
64.03%
S&P 500 (^GSPC)
106.58%

Compare To: NRXS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: NRXS

View More

Valuation Measures

Annual
As of 5/14/2025
  • Market Cap

    16.35M

  • Enterprise Value

    13.13M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    5.84

  • Price/Book (mrq)

    7.92

  • Enterprise Value/Revenue

    4.89

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -169.85%

  • Return on Equity (ttm)

    -2,480.49%

  • Revenue (ttm)

    2.69M

  • Net Income Avi to Common (ttm)

    -8.45M

  • Diluted EPS (ttm)

    -1.2200

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    3.7M

  • Total Debt/Equity (mrq)

    22.90%

  • Levered Free Cash Flow (ttm)

    -3.65M

Research Analysis: NRXS

View More

Company Insights: NRXS

Research Reports: NRXS

View More

People Also Watch